SGLT2 Inhibitors: The Dawn of a New Era in Cardio-Metabolic Therapeutics

Am J Cardiovasc Drugs. 2022 Jan;22(1):1-4. doi: 10.1007/s40256-021-00495-5. Epub 2021 Aug 30.

Author

Prakash Deedwania^{1

2}

Affiliations

¹ UCSF School of Medicine, San Francisco, CA, USA. deed@ucsf.edu.
² UCSF Fresno, Academic Suite, East Kashian Lane, Fresno, CA, 93701, USA. deed@ucsf.edu.

PMID: 34458960
DOI: 10.1007/s40256-021-00495-5

No abstract available

Publication types

Editorial

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Heart
Humans
Hypoglycemic Agents / pharmacology
Hypoglycemic Agents / therapeutic use
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors